Just one year after successfully demonstrating lab-scale production of human insulin using synthetic biology techniques, rBIO recently concluded a successful optimization project with WashU, and firms its path toward commercialization and large-scale production.
BIO Doubles Insulin Output Over Legacy Manufacturing Methods, Putting Company on Track to Reduce Insulin Costs by 30%
View Content